206 related articles for article (PubMed ID: 18053985)
1. Interactions of myeloma cells with osteoclasts promote tumour expansion and bone degradation through activation of a complex signalling network and upregulation of cathepsin K, matrix metalloproteinases (MMPs) and urokinase plasminogen activator (uPA).
Hecht M; von Metzler I; Sack K; Kaiser M; Sezer O
Exp Cell Res; 2008 Mar; 314(5):1082-93. PubMed ID: 18053985
[TBL] [Abstract][Full Text] [Related]
2. Osteoblasts promote migration and invasion of myeloma cells through upregulation of matrix metalloproteinases, urokinase plasminogen activator, hepatocyte growth factor and activation of p38 MAPK.
Hecht M; Heider U; Kaiser M; von Metzler I; Sterz J; Sezer O
Br J Haematol; 2007 Aug; 138(4):446-58. PubMed ID: 17593251
[TBL] [Abstract][Full Text] [Related]
3. miR-29b negatively regulates human osteoclastic cell differentiation and function: implications for the treatment of multiple myeloma-related bone disease.
Rossi M; Pitari MR; Amodio N; Di Martino MT; Conforti F; Leone E; Botta C; Paolino FM; Del Giudice T; Iuliano E; Caraglia M; Ferrarini M; Giordano A; Tagliaferri P; Tassone P
J Cell Physiol; 2013 Jul; 228(7):1506-15. PubMed ID: 23254643
[TBL] [Abstract][Full Text] [Related]
4. Osteoclastic bone degradation and the role of different cysteine proteinases and matrix metalloproteinases: differences between calvaria and long bone.
Everts V; Korper W; Hoeben KA; Jansen ID; Bromme D; Cleutjens KB; Heeneman S; Peters C; Reinheckel T; Saftig P; Beertsen W
J Bone Miner Res; 2006 Sep; 21(9):1399-408. PubMed ID: 16939398
[TBL] [Abstract][Full Text] [Related]
5. Osteoprotegerin differentially regulates protease expression in osteoclast cultures.
Wittrant Y; Couillaud S; Theoleyre S; Dunstan C; Heymann D; Rédini F
Biochem Biophys Res Commun; 2002 Apr; 293(1):38-44. PubMed ID: 12054560
[TBL] [Abstract][Full Text] [Related]
6. Quantification of the expression levels of lysosomal cysteine proteinases in purified human osteoclastic cells by competitive RT-PCR.
Ishibashi O; Inui T; Mori Y; Kurokawa T; Kokubo T; Kumegawa M
Calcif Tissue Int; 2001 Feb; 68(2):109-16. PubMed ID: 11310346
[TBL] [Abstract][Full Text] [Related]
7. Biological aspects of altered bone remodeling in multiple myeloma and possibilities of pharmacological intervention.
Kupisiewicz K
Dan Med Bull; 2011 May; 58(5):B4277. PubMed ID: 21535989
[TBL] [Abstract][Full Text] [Related]
8. Proteolytic excision of a repressive loop domain in tartrate-resistant acid phosphatase by cathepsin K in osteoclasts.
Ljusberg J; Wang Y; Lång P; Norgård M; Dodds R; Hultenby K; Ek-Rylander B; Andersson G
J Biol Chem; 2005 Aug; 280(31):28370-81. PubMed ID: 15929988
[TBL] [Abstract][Full Text] [Related]
9. Resveratrol inhibits myeloma cell growth, prevents osteoclast formation, and promotes osteoblast differentiation.
Boissy P; Andersen TL; Abdallah BM; Kassem M; Plesner T; Delaissé JM
Cancer Res; 2005 Nov; 65(21):9943-52. PubMed ID: 16267019
[TBL] [Abstract][Full Text] [Related]
10. Urokinase receptor mediates osteoclastogenesis via M-CSF release from osteoblasts and the c-Fms/PI3K/Akt/NF-κB pathway in osteoclasts.
Kalbasi Anaraki P; Patecki M; Tkachuk S; Kiyan Y; Haller H; Dumler I
J Bone Miner Res; 2015 Feb; 30(2):379-88. PubMed ID: 25196912
[TBL] [Abstract][Full Text] [Related]
11. Mechanical strain effect on bone-resorbing activity and messenger RNA expressions of marker enzymes in isolated osteoclast culture.
Kurata K; Uemura T; Nemoto A; Tateishi T; Murakami T; Higaki H; Miura H; Iwamoto Y
J Bone Miner Res; 2001 Apr; 16(4):722-30. PubMed ID: 11316000
[TBL] [Abstract][Full Text] [Related]
12. Calvarial osteoclasts express a higher level of tartrate-resistant acid phosphatase than long bone osteoclasts and activation does not depend on cathepsin K or L activity.
Perez-Amodio S; Jansen DC; Schoenmaker T; Vogels IM; Reinheckel T; Hayman AR; Cox TM; Saftig P; Beertsen W; Everts V
Calcif Tissue Int; 2006 Oct; 79(4):245-54. PubMed ID: 17033726
[TBL] [Abstract][Full Text] [Related]
13. Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor.
Gravallese EM; Manning C; Tsay A; Naito A; Pan C; Amento E; Goldring SR
Arthritis Rheum; 2000 Feb; 43(2):250-8. PubMed ID: 10693863
[TBL] [Abstract][Full Text] [Related]
14. Plasminogen activators are involved in the degradation of bone by osteoclasts.
Everts V; Daci E; Tigchelaar-Gutter W; Hoeben KA; Torrekens S; Carmeliet G; Beertsen W
Bone; 2008 Nov; 43(5):915-20. PubMed ID: 18691680
[TBL] [Abstract][Full Text] [Related]
15. Cathepsin K mRNA detection is restricted to osteoclasts during fetal mouse development.
Dodds RA; Connor JR; Drake F; Feild J; Gowen M
J Bone Miner Res; 1998 Apr; 13(4):673-82. PubMed ID: 9556067
[TBL] [Abstract][Full Text] [Related]
16. Myeloma cells can directly contribute to the pool of RANKL in bone bypassing the classic stromal and osteoblast pathway of osteoclast stimulation.
Lai FP; Cole-Sinclair M; Cheng WJ; Quinn JM; Gillespie MT; Sentry JW; Schneider HG
Br J Haematol; 2004 Jul; 126(2):192-201. PubMed ID: 15238139
[TBL] [Abstract][Full Text] [Related]
17. Matrix metalloproteinases (MMP) and cathepsin K contribute differently to osteoclastic activities.
Delaissé JM; Andersen TL; Engsig MT; Henriksen K; Troen T; Blavier L
Microsc Res Tech; 2003 Aug; 61(6):504-13. PubMed ID: 12879418
[TBL] [Abstract][Full Text] [Related]
18. Degradation of the organic phase of bone by osteoclasts: a secondary role for lysosomal acidification.
Henriksen K; Sørensen MG; Nielsen RH; Gram J; Schaller S; Dziegiel MH; Everts V; Bollerslev J; Karsdal MA
J Bone Miner Res; 2006 Jan; 21(1):58-66. PubMed ID: 16355274
[TBL] [Abstract][Full Text] [Related]
19. Proteolytic processing and polarized secretion of tartrate-resistant acid phosphatase is altered in a subpopulation of metaphyseal osteoclasts in cathepsin K-deficient mice.
Zenger S; Hollberg K; Ljusberg J; Norgård M; Ek-Rylander B; Kiviranta R; Andersson G
Bone; 2007 Nov; 41(5):820-32. PubMed ID: 17765026
[TBL] [Abstract][Full Text] [Related]
20. Cathepsin K deficiency partially inhibits, but does not prevent, bone destruction in human tumor necrosis factor-transgenic mice.
Schurigt U; Hummel KM; Petrow PK; Gajda M; Stöckigt R; Middel P; Zwerina J; Janik T; Bernhardt R; Schüler S; Scharnweber D; Beckmann F; Saftig P; Kollias G; Schett G; Wiederanders B; Bräuer R
Arthritis Rheum; 2008 Feb; 58(2):422-34. PubMed ID: 18240253
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
